COMPANY SUMMARY
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Financial Summary
| Share Statistics |
COLL |
Industry Median |
Percentile (All Stocks) |
| Market Cap (Mil) |
$786.8 |
$447.9 |
43% |
|
| Shares Out (Mil) |
39.1 |
46.7 |
42% |
|
| Institutional Ownership |
99.1% |
80.9% |
85% |
|
| Float (Mil) |
28.3 |
46.8 |
35% |
|
| Beta |
0.73 |
0.74 |
42% |
|
| Avg Daily Volume (000s) |
713 |
342 |
62% |
|
Price Change (52-week) |
(46.5%) |
54.7% |
21% |
|
| Growth |
COLL |
Industry Median |
Percentile (All Stocks) |
| Sales (5yr) |
20.3% |
6.1% |
82% |
|
| Net Income (5yr) |
18.6% |
(1.6%) |
71% |
|
| EPS (5yr) |
17.9% |
15.0% |
65 |
|
| Dividends (5yr) |
0.0% |
0.0% |
0% |
|
| Cash Flow (5yr) |
91.6% |
(15.1%) |
98% |
|
| Estimates |
Qtrly |
Current Fiscal Year |
Next Fiscal Year |
| # of Estimates |
7 |
7 |
7 |
| Current EPS |
$1.894 |
$7.465 |
$7.078 |
| Month Ago EPS |
$1.902 |
$7.323 |
$6.635 |
| # Rev Up |
2 |
1 |
0 |
| # Rev Down |
0 |
0 |
1 |
| Three Months Ago EPS |
$2.003 |
$7.532 |
$6.975 |
| Year/Year Chg |
217.8% |
330.3% |
324.8% |
| Financials |
COLL |
Industry Median |
Percentile (All Stocks) |
| Sales (TTM) (Mil) |
$815 |
$303 |
47% |
|
| Net Income (TTM) (Mil) |
$38 |
($10) |
52% |
|
| EPS (TTM) |
$1.193 |
($0.600) |
63% |
|
| Operating Cash Flow (TTM) (Mil) |
$338 |
($7) |
66% |
|
| Net Cash Flow (TTM) (Mil) |
($5) |
$1 |
36% |
|
| Long-Term Debt (Q1) (Mil) |
$1,146 |
$6 |
68% |
|
| Enterprise Value (Q1) (Mil) |
$1,815 |
$408 |
48% |
|
| Valuation |
COLL |
Industry Median |
Percentile (All Stocks) |
| P/B |
2.65 |
2.19 |
65% |
|
| P/E |
22.3 |
22.1 |
59% |
|
| Dividend Yield |
0.0% |
0.0% |
0% |
|
| PEG (5yr hist) |
1.2 |
1.2 |
55% |
|
| Ratios |
COLL |
Industry Median |
Percentile (All Stocks) |
| Gross Margin |
89.4% |
69.5% |
93% |
|
| Net Margin |
4.7% |
3.9% |
46% |
|
| ROA |
2.1% |
(22.7%) |
55% |
|
| ROE |
13.4% |
(25.0%) |
66% |
|
| Liabilities to Assets |
85.9% |
31.8% |
80% |
|
| F-Score |
4 |
3 |
34% |
|
Passing Stock Screens
As of 11/13/2026, from a list of 60 stock screening strategies,
COLL meetings the criteria of 1 screen:
Stock Screen
FACTOR STRATEGY
Price-to-Free-Cash-Flow Screen
Factors: Value
An exploration of the basics of cash flow analysis and the implementation of a price-to-free-cash-flow screen.